To date, reports including patients relapsed after HSCT are available on CAR-T cells directed against myeloid antigens, such as CD33, CD38, and CD123, as well as CD19, which is aberrantly expressed in AML with t(8;21) [109,110,111,112,113]. Here, CD33 is linked to acute myeloid leukemia.